News
Jun. 05, 2023
From June 5 to 8, 2023, the BIO International Convention took place in Boston, USA, marking the largest global event in the biotechnology industry. The event brought together leading biopharmaceutical companies, investors, and collaborators from around the world, with numerous partnership activities taking place throughout the conference. ExCell Bio made a spectacular debut!
Products Attract Attention, Performance Praised
During the exhibition, ExCell Bio showcased its three main product lines: Fetal Bovine Serum (FBS), Serum-Free Media, and Identification Reagents. With enthusiasm, sincerity, and professionalism, ExCell Bio's team introduced the company's self-developed capabilities, product performance, and expert services to global clients. The company received widespread praise and recognition from international visitors.
Global Expansion: A Strong Foundation for Future Growth
With years of industry experience, intense investment in R&D, and a robust global supply chain network, ExCell Bio is fully equipped to expand internationally. The company operates serum factories in China, Uruguay, and Australia. Recently, the second serum factory in Uruguay, ARTICA, was successfully completed. This facility will serve as a key overseas base for fetal bovine serum production, supporting ExCell Bio’s expansion into South America and facilitating its global business outreach. This marks the official entry of ExCell Bio’s fetal bovine serum into the "World for World" expansion 2.0 era.
GMP Facilities Meet EU and FDA Standards, Supporting Global Commercialization
ExCell Bio's GMP-certified production workshops for both dry powder and liquid serum-free media meet EU and FDA certification standards, with a production capacity reaching millions of liters. Some products have also obtained Drug Master File (DMF) certification. This ensures that ExCell Bio fully meets the diverse needs of biopharmaceutical clients for safe, stable, compliant, and effective raw materials in commercial production.